Drug Trial Radar · NCT06082063
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: Jan 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Jul 1, 2024
Primary completion
Jul 1, 2029
Study completion Jul 1, 2029
Sponsor
- Lead sponsor
- Steno Diabetes Center CopenhagenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aarhus University Hospital; Steno Diabetes Center Nordjylland; Steno Diabetes Center Odense; Slagelse Hospital; Nykøbing Falster County Hospital; Zealand University Hospital; Hillerod Hospital, Denmark; Copenhagen University Hospital, Rigshospitalet; Hvidovre University Hospital; Regionshospitalet Viborg, Skive; Randers Regional Hospital; Herning Hospital; Esbjerg Hospital - University Hospital of Southern Denmark; Regionshospitalet Silkeborg; Bispebjerg Hospital; Regionshospitalet Horsens
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, randomised, open-labelled, multi-center study. The aim of the Steno 1 study is to test multifactorial intervention in individuals with type 1 diabetes at high risk of CVD with ambitious treatment targets. We will include 2000 participants. Follow-up is 5 years.
Conditions
- Cardiovascular Diseases
- Heart Failure
- Type 1 Diabetes
- Kidney Failure
Interventions
Aspirin tabletDrug
Antiplatelet treatment: with aspirin 75mg OD is mandatory except for concomitant anticoagulant therapy or allergy. In case of allergy clopidogrel will be used.
SemaglutideDrug
GLP-1RA treatment: With semaglutide once weekly individually stepped highest tolerable dose according to standard guidelines aiming at 1 mg/week for persons with HbA1c \>53 mmol/mol or BMI\>25 kg/m2 and/or ischemic heart disease and/or stroke. For safety see below under benefits and risks. Investigators should pay attention to the need for adjustment in insulin dose after initiation of GLP-1RA treatment.
SotagliflozinDrug
SGLT2i treatment with sotagliflozin 200 mg once daily for persons with UACR \>30 mg/g and eGFR \< 45 ml/min/1.73 m2 and for persons with a diagnosis of HF. For safety see below under benefits and risks. The limit of eGFR (\<45ml/min) for initiation of SGLT2i treatment is set to reduce risk of ketoacidosis. SGLT2i treatment should not be offered to participants on insulin pump therapy, to reduce risk of ketoacidosis. Investigators should pay attention to the need for adjustment in insulin dose after initiation of SGLT2i treatment.
FinerenoneDrug
Finerenone: 10 mg once daily titrated to 20 mg as add-on in persons with persistent albuminuria (\>30 mg/g) despite RAS blockade.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MACE + HHFTime frame: 5 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark · Recruiting
Steno Diabetes Center Copenhagen
Herlev, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.